Ability of the Glasgow Prognostic Score to predict the tolerability and efficacy of platinum-combination chemotherapy among elderly patients with advanced non-small cell lung cancer-Reference-Cited by-同舟云学术

Ability of the Glasgow Prognostic Score to predict the tolerability and efficacy of platinum-combination chemotherapy among elderly patients with advanced non-small cell lung cancer

Published:2021 Issue:3.4 Volume:68 Page:260-264
ISSN:1343-1420
Container-title:The Journal of Medical Investigation
language:en
Short-container-title:J. Med. Invest.

Author:

Nakashima Kazuhisa¹,Hata Kojiro¹,Hotta Takamasa¹,Tanaka Seiko¹,Mitarai Yuki¹,Okuno Takae¹,Tanino Akari¹,Nakao Mika¹,Amano Yoshihiro¹,Hamaguchi Megumi¹,Okimoto Tamio¹,Hamaguchi Shunichi¹,Nagao Taishi¹,Kurimoto Noriaki¹,Isobe Takeshi¹,Tsubata Yukari¹

Affiliation:

1. Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Shimane University Faculty of Medicine, Shimane, Japan

Publisher

University of Tokushima Faculty of Medicine

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.jstage.jst.go.jp/article/jmi/68/3.4/68_260/_pdf

Reference19 articles.

1. 1. NCCN Clinical Practice Guideline in Oncology : Non-Small Cell Lung Cancer. Version 2.2018. http://www.nccn.org.

2. 2. Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavolé A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Dansin E, Poudenx M, Molinier O, Vaylet F, Moro-Sibilot D, Herman D, Bennouna J, Tredaniel J, Ducoloné A, Lebitasy MP, Baudrin L, Laporte S, Milleron B ; Intergroupe Francophone de Cancérologie Thoracique : Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer : IFCT-0501 randomised, phase 3 trial. Lancet 378 : 1079-1088, 2011

3. 3. Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL, Renschler MF : Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer : final results of a phase III trial. J Clin Oncol 30 : 2055-2062, 2012

4. 4. Socinski MA, Langer CJ, Okamoto I, Hon JK, Hirsh V, Dakhil SR, Page RD, Orsini J, Zhang H, Renschler MF : Safety and efficacy of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. Ann Oncol 24 : 314-321, 2013

5. 5. Okamoto I, Nokihara H, Nomura S, Niho S, Sugawara S, Horinouchi H, Azuma K, Yoneshima Y, Murakami H, Hosomi Y, Atagi S, Ozaki T, Horiike A, Fujita Y, Okamoto H, Ando M, Yamamoto N, Ohe Y, Nakagawa K : Comparison of carboplatin plus pemetrexed followed by maintenance pemetrexed with docetaxel monotherapy in elderly patients with advanced nonsquamous non-small cell lung cancer : a phase 3 randomized clinical trial. JAMA Oncol 6 : e196828, 2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What is hemoglobin, albumin, lymphocyte, platelet (HALP) score? A comprehensive literature review of HALP’s prognostic ability in different cancer types;Oncotarget;2023-02-25

2. Clinical Efficacy and Safety Analysis of PD-1/PD-L1 Inhibitor vs. Chemotherapy in the Treatment of Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis;BioMed Research International;2022-06-25